Alexza Pharmaceuticals

Pipeline Opportunities

Current partners and available partnership opportunities

Through licensing relationships, research collaborations and strategic alliances that complement and extend the Staccato technology, Alexza is interested in collaborations that have the potential to create superior products and improve patients’ lives.

Commercial product

ADASUVE^® Staccato^® loxapine

For the acute treatment of agitation associated with schizophrenia or bipolar I disorder in adults
Ferrer holds commercial rights in Europe, Latin America, Russia, the CIS countries, the Middle East and North Africa countries, Korea, the Philippines, and Thailand
Lee’s Pharm holds commercial rights in China
Commercial opportunity for the US is available
Available for licensing in all other territories

Active programs in development with partners

Staccato^® alprazolam

For the acute treatment of epileptic seizures
UCB holds worldwide development and commercial rights

Active programs led by Alexza

Staccato^® apomorphine

For the rapid, acute treatment of OFF episodes in patients with Parkinson’s disease on stable anti-Parkinson medication

Staccato^® granisetron

For the acute treatment of cyclic vomiting syndrome

To see our pipeline click here.

For more information about our programs click here.

To discuss partnership and licensing opportunities, please contact our Business Development Group.

Alexza Development Program Information*

Alexza has a number of programs in active development in addition to our approved commercial product ADASUVE^® (loxapine) inhalation powder. For full prescribing information, including boxed warning, visit ADASUVE.com or the EMA website.

Active programs in development with partners

Staccato^® alprazolam

Under development for the acute treatment of epileptic seizures

Epilepsy is a condition that causes seizures and is the fourth most common neurological problem in the world according to the Epilepsy Foundation. Approximately three million patients in the United States are living with epilepsy, and one-third of those patients have uncontrolled seizures that are not effectively treated by available therapies. Twenty percent of patients with uncontrolled seizures have a seizure pattern that they can predict and are in need of a rescue treatment to stop ongoing seizure activity before their seizure progresses. Stopping seizure activity early before it has the opportunity to progress may allow patients to continue with their normal activities and help prevent neurological damage.

Staccato alprazolam is being developed for the treatment of acute uncontrolled seizures in patients with epilepsy. Staccato alprazolam is an investigational combination of Alexza’s proprietary Staccato system with alprazolam, a drug belonging to the benzodiazepine class of compounds. The rapidity by which a medication can be delivered to the systemic circulation and then to the brain may play a role in reducing the time needed to treat seizures and reducing the likelihood of damage to the central nervous system.

The potential benefits of the Staccato system include a fast delivery to the bloodstream, comparable to IV administration, and ease of use in the outpatient setting. Clinical studies will evaluate, among other things, whether Staccato alprazolam could be administered immediately after seizure activity is recognized.

UCB holds worldwide development and commercial rights. Find out more at UCB.com and follow them on Twitter: @UCB_news.

Lee’s Pharm holds rights for China and Southeast Asia territory. For more information, visit Lee’s Pharmaceutical Holdings Limited.

Active programs led by Alexza

Staccato^® apomorphine

Under development for the rapid, acute treatment of OFF episodes in patients with Parkinson’s disease on stable anti-Parkinson medication

Parkinson’s disease, or PD, is a progressive neurodegenerative disorder that is characterized by a broad spectrum of motor and non-motor features that can have an impact on the function of the patient. One of these clinical features is acute and intermittent hypomobility or OFF episodes which tend to manifest in more advanced patients.

Staccato apomorphine (apomorphine hydrochloride for inhalation) is being developed for the treatment of motor fluctuations in Parkinson’s disease patients who do not respond to oral treatment.

Staccato apomorphine represents a potential new dosage form of apomorphine. It is a single-use, drug-device combination product candidate that delivers aerosolized apomorphine. Inhalation as route of administration via the Staccato device may allow apomorphine to be delivered non-invasively with rapid IV-like pharmacokinetics to individuals.

The development program for Staccato apomorphine will evaluate, among other things, whether inhalation via Staccato delivery could lead to a better absorption profile and provide more rapid and better control of OFF episodes. Because the patient is only required to take a normal breath for delivery of the aerosolized drug and because it is a non-invasive treatment, it could, if approved, represent a contribution to patient care over current treatment.

The program is currently completing Phase 1 study in healthy volunteers and patients.

Alexza owns full development and commercial rights to Staccato apomorphine.

Staccato^® granisetron

Under development for the acute treatment of cyclic vomiting syndrome

Cyclic vomiting syndrome (CVS) is an idiopathic chronic disorder characterized by sudden episodes of nausea and rapid-fire vomiting lasting for 1-5 days followed by symptom-free periods. This alternating pattern of disease and disease-free periods distinguishes CVS from other gastrointestinal disorders. There is no current drug therapy approved for treatment of CVS. Antiemetic agents have been reported to be a key component of supportive care for acute abortive treatment during the prodromal and emetic phases of CVS.

We are currently developing Staccato granisetron as an acute, PRN (as needed) treatment for CVS. Staccato granisetron represents a potential new dosage form of granisetron. Inhalation as route of administration via the Staccato device would allow granisetron to be delivered via a non-invasive, non-oral route, potentially with rapid IV-like pharmacokinetics to individuals.

We are currently conducting a Phase 2 study in patients with Cyclic Vomiting Syndrome at 18 study sites in the US. Additional information can be found at CVSHOPE.com or on ClinicalTrials.gov under NCT04645953.

Alexza owns full development and commercial rights to Staccato granisetron.

* All products described on this page are investigational and have not been approved for any use by the United States Food and Drug Administration (FDA) or any other health authority. The safety and efficacy of these investigational products have not been established.

Staccato OBT

Pipeline Opportunities

Current partners and available partnership opportunities

Commercial product

Active programs in development with partners

Active programs led by Alexza

Alexza Development Program Information*

Active programs in development with partners

Staccato® alprazolam

Active programs led by Alexza

Staccato® apomorphine

Staccato® granisetron

Staccato^® alprazolam

Staccato^® apomorphine

Staccato^® granisetron